Toxins 2013, 5(11), 2058-2073; doi:10.3390/toxins5112058
Article

Association between Free Light Chain Levels, and Disease Progression and Mortality in Chronic Kidney Disease

1,2email, 1,2email, 1,3email, 4email, 5email, 1,6email, 1,7,* email and 1
Received: 24 September 2013; in revised form: 28 October 2013 / Accepted: 29 October 2013 / Published: 8 November 2013
(This article belongs to the Special Issue Uremic Toxins)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Immunoglobulin free light chains (FLCs) form part of the middle molecule group of uremic toxins. Accumulation of FLCs has been observed in patients with chronic kidney disease (CKD). The aim of the present study was to measure FLC levels in patients at different CKD stages and to assess putative associations between FLC levels on one hand and biochemical/clinical parameters and mortality on the other. One hundred and forty patients at CKD stages 2-5D were included in the present study. Routine clinical biochemistry assays and assays for FLC kappa (κ) and lambda (λ) and other uremic toxins were performed. Vascular calcification was evaluated using radiological techniques. The enrolled patients were prospectively monitored for mortality. Free light chain κ and λ levels were found to be elevated in CKD patients (especially in those on hemodialysis). Furthermore, FLC κ and λ levels were positively correlated with inflammation, aortic calcification and the levels of various uremic toxins levels. A multivariate linear regression analysis indicated that FLC κ and λ levels were independently associated with CKD stages and β2 microglobulin levels. Elevated FLC κ and λ levels appeared to be associated with mortality. However, this association disappeared after adjustment for a propensity score including age, CKD stage and aortic calcification. In conclusion, our results indicate that FLC κ and λ levels are elevated in CKD patients and are associated with inflammation, vascular calcification and levels of other uremic toxins. The observed link between elevated FLC levels and mortality appears to depend on other well-known factors.
Keywords: uremic toxins; free light chain; chronic kidney disease
PDF Full-text Download PDF Full-Text [326 KB, uploaded 8 November 2013 15:42 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Desjardins, L.; Liabeuf, S.; Lenglet, A.; Lemke, H.-D.; Vanholder, R.; Choukroun, G.; Massy, Z.A.; European Uremic Toxin (EUTox) Work Group. Association between Free Light Chain Levels, and Disease Progression and Mortality in Chronic Kidney Disease. Toxins 2013, 5, 2058-2073.

AMA Style

Desjardins L, Liabeuf S, Lenglet A, Lemke H-D, Vanholder R, Choukroun G, Massy ZA, European Uremic Toxin (EUTox) Work Group. Association between Free Light Chain Levels, and Disease Progression and Mortality in Chronic Kidney Disease. Toxins. 2013; 5(11):2058-2073.

Chicago/Turabian Style

Desjardins, Lucie; Liabeuf, Sophie; Lenglet, Aurélie; Lemke, Horst-Dieter; Vanholder, Raymond; Choukroun, Gabriel; Massy, Ziad A.; European Uremic Toxin (EUTox) Work Group. 2013. "Association between Free Light Chain Levels, and Disease Progression and Mortality in Chronic Kidney Disease." Toxins 5, no. 11: 2058-2073.


Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert